"We are pleased to welcome Andrew to the executive leadership team of AltheaDx," said Jorge Garces, President and Chief Executive Officer. "He has a proven track record with both venture-backed and public companies and will provide the leadership and strategic vision required as we grow our business."
AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx's IDgenetix® pharmacogenetic testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. AltheaDx is a CAP-accredited, CLIA-certified laboratory located in San Diego, CA. For more information, visit www.altheadx.com.
Forward Looking Statements
This press release may contain forward-looking statements regarding the business strategy of AltheaDx. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity or performance to differ materially from those expressed or implied by these forward looking statements. These statements reflect the views of AltheaDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/altheadx-announces-appointment-of-chief-financial-officer-300349934.html
SOURCE AltheaDx, Inc.